Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer

OncoImmunology

Volumn 1, Issue 2, 2012, Pages 152-161

  Zhao, Ende ^a,b   Wang, Lin ^a,b   Dai, Jinlu ^c   Kryczek, Ilona ^a   Wei, Shuang ^a   Vatan, Linda ^a   Altuwaijri, Saleh ^a   Sparwasser, Tim ^d   Wang, Guobin ^b   Keller, Evan T ^c   Zou, Weiping ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

Bone marrow; CXCL12; CXCR4; Dendritic cell; Prostate cancer; RANK; RANKL; Regulatory T cell

Indexed keywords

CD40 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; COLONY STIMULATING FACTOR 1; GAMMA INTERFERON; INTERLEUKIN 2; KI 67 ANTIGEN; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STROMAL CELL DERIVED FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DESTRUCTION; BONE MARROW METASTASIS; BONE MINERAL; CARCINOGENESIS; CELL EXPANSION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 84871718282     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.2.18480     Document Type: Article

References (50)

1. Zhao E, Xu H, Wang L, Kryczek I, Wu K, Hu Y, et al. Bone marrow and the control of immunity. Cell Mol Immunol 2011. In press; http://dx.doi.org/10.1038/cmi.2011.47
2. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998; 8:363-72; http://dx.doi.org/10.1016/S1074-7613(00)80541-5
3. Becker TC, Coley SM, Wherry EJ, Ahmed R. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J Immunol 2005; 174:1269-73
4. + T cells. Immunity 2005; 22:259-70; http://dx.doi.org/10.1016/j.immuni.2005. 01.008
5. Tripp RA, Topham DJ,Watson SR, Doherty PC. Bone marrow can function as a lymphoid organ during a primary immune response under conditions of disrupted lymphocyte trafficking. J Immunol 1997; 158: 3716-20
6. Feuerer M, Beckhove P, Garbi N, Mahnke Y, Limmer A, Hommel M, et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 2003; 9:1151-7; http://dx.doi.org/ 10.1038/nm914
7. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, et al. Therapy of human tumors in NOD/ SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001; 7:452-8; http://dx.doi.org/10.1038/86523
8. Feuerer M, Rocha M, Bai L, Umansky V, Solomayer EF, Bastert G, et al. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int J Cancer 2001; 92:96-105; http://dx.doi.org/10.1002/1097-0215(200102)9999: 9999,::AID-IJC1152.3.0.CO;2-Q
9. Zou L, Barnett B, Safah H, Larussa VF, Evdemon-Hogan M, Mottram P, et al. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004; 64:8451-5; http://dx.doi.org/10.1158/0008-5472.CAN-04-1987
10. Wan YY, Flavell RA. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci USA 2005; 102:5126-31; http://dx.doi.org/10.1073/pnas.0501701102
11. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy. J Exp Med 2003;198:1753-7.
12. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998; 160:1212-8
13. + immunoregulatory T cells is antigen nonspecific. J Immunol 2000; 164:183-90
14. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7:1339-46; http://dx.doi.org/10. 1038/nm1201-1339
15. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9:562-7; http://dx.doi.org/10. 1038/nm863
16. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005; 146:1727-36; http://dx.doi.org/10.1210/en.2004-1211
17. Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichman RS, et al. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 2003; 97:739-47; http://dx.doi.org/10. 1002/cncr.11181
18. Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007; 13:62-9; http://dx.doi.org/10.1038/nm1519
19. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107:1235-44; http://dx.doi.org/10.1172/JCI11685
20. Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z, et al. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis 2004; 21:399-408; http://dx.doi.org/10. 1007/s10585-005-0056-6
21. Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason J, Eberl G, et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med 2007; 204:57-63; http://dx. doi.org/10.1084/jem.20061852
22. Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002; 17:737-47; http://dx.doi.org/10.1016/S1074-7613(02) 00480-6
23. Schreiber H, Wu TH, Nachman J, Kast WM. Immunodominance and tumor escape. Semin Cancer Biol 2002; 12:25-31; http://dx.doi. org/10.1006/scbi.2001.0401
24. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263-74; http://dx. doi.org/10.1038/nrc1586
25. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6:295-307; http://dx.doi.org/10.1038/nri1806
26. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27; http://dx.doi.org/10.1038/nri1936
27. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832-7
28. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Cook K, et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005; 20:318-29; http:// dx.doi.org/10.1359/JBMR.041109
29. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3:687-94; http://dx.doi.org/10.1038/ni813
30. Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med 2002; 196:851-7; http://dx.doi.org/10. 1084/jem.20020190
31. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4:665-74; http://dx.doi.org/10. 1038/nri1435
32. Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W, Banerjee M, et al. Interleukin-2 Administration Alters the CD4+FOXP3+ T-Cell Pool and Tumor Trafficking in Patients with Ovarian Carcinoma. Cancer Res 2007; 67:7487-94; http://dx.doi.org/10. 1158/0008-5472.CAN-07-0565
33. Kryczek I, Wei S, Vatan L, Escara-Wilke J, Szeliga W, Keller ET, et al. Cutting Edge: Opposite Effects of IL-1 and IL-2 on the Regulation of IL-17+ T Cell Pool IL-1 Subverts IL-2-Mediated Suppression. J Immunol 2007; 179:1423-6
34. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-86; http://dx.doi. org/10.1084/jem.20030152
35. Green EA, Choi Y, Flavell RA. Pancreatic lymph nodederived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 2002; 16:183-91; http://dx.doi.org/10.1016/S1074-7613(02)00279-0
36. Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006; 12:1372-9; http://dx.doi.org/ 10.1038/nm1518
37. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006; 24:33-63; http://dx.doi.org/10.1146/ annurev.immunol.24.021605.090646
38. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756-65; http://dx.doi.org/10.1056/NEJMoa0809493
39. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354:821-31; http://dx.doi.org/10.1056/NEJMoa044459
40. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402:304-9; http://dx.doi.org/10.1038/46303
41. Zaiss MM, Axmann R, Zwerina J, Polzer K, Guckel E, Skapenko A, et al. Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum 2007; 56:4104-12; http://dx.doi.org/10.1002/art.23138
42. Zaiss MM, Frey B, Hess A, Zwerina J, Luther J, Nimmerjahn F, et al. Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol 2010; 184:7238-46; http://dx.doi.org/10.4049/jimmunol.0903841
43. McCabe NP, Madajka M, Vasanji A, Byzova TV. Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition. Clin Exp Metastasis 2008; 25:581-90; http://dx.doi.org/10.1007/s10585-008-9175-1
44. Dai J, Lu Y, Yu C, Keller JM, Mizokami A, Zhang J, et al. Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors. Cancer Res 2010; 70:5014-23; http://dx.doi.org/10.1158/0008-5472.CAN-10-0100
45. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; http://dx.doi.org/10.1038/nm1093
46. Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009; 69:3995-4000; http://dx.doi.org/10.1158/ 0008-5472.CAN-08-3804
47. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203:871-81; http://dx.doi.org/10.1084/jem.20050930
48. Kryczek I, Wei S, Zou L, Zhu G, Mottram P, Xu H, et al. Cutting Edge: Induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 2006; 177:40-4
49. Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 1995; 92:1327-31; http://dx.doi.org/ 10.1073/pnas.92.5.1327
50. Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010; 70:7788-99; http://dx.doi. org/10.1158/0008-5472.CAN-10-1736